Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 11, 2009

View Archived Issues

AIPL1 gene therapy shows promise for retinal dystrophies / News in Context

Alnylam and Tekmira enter research collaboration for systemic delivery of RNAi therapeutics

FDA places Repros' INDs for Proellex on clinical hold for safety reasons

Eden and Omnio sign agreement for production of protein candidate for wound healing

GSK to acquire Nabi's PentaStaph pentavalent S. aureus vaccine

Nanotherapeutics updates clinical progress of NanoBUP and NanoDOX

Antisoma to discontinue development of AS-1402 for breast cancer

European Commission grants orphan drug designation to Alexion's Soliris in aHUS

High interpatient variability of sildenafil exposure in neonates with PHT

Escitalopram treatment reduces benzodiazepine withdrawal symptoms

BLX-155 shows thrombolytic efficacy in porcine model of arteriovenous graft failure

Solulin restores cerebral blood flow and reduces infarct size in thrombotic stroke model

Diannexin exhibits potent in vitro and in vivo antithrombotic effects

PharmaMar reports discovery of natural compounds for cancer treatment

AstraZeneca claims novel AR ligands for the treatment of prostate cancer

Banyu presents glucokinase activators for the treatment of diabetes and obesity

Avila Therapeutics discloses new protease inhibitors for hepatitis C virus infection

Lilly discovers new MR antagonists for chronic kidney disease therapy

Curis and Debiopharm enter license agreement for CUDC-305 and Hsp90 technology

Spectrum acquires full rights and intellectual property to Altair's RenaZorb in all fields

ViroPharma initiates dosing in phase I trial of nontoxigenic C. difficile

Hisamitsu reports results from phase II study of HOB-294 in overactive bladder

Sepracor submits NDS to Health Canada for Stedesa as adjunctive therapy for epilepsy

FDA advisory committee to meet in September 2009 to review Allos' NDA for pralatrexate

FDA approves new formulation of Actelion's Ventavis for PAH

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 19, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...